Antiviral signaling of a type III CRISPR-associated deaminase.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39666823.
- Also identified by DOI 10.1126/science.adr0393.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prokaryotes have evolved diverse defense strategies against viral infection, including foreign nucleic acid degradation by CRISPR-Cas systems and DNA and RNA synthesis inhibition through nucleotide pool depletion. Here, we report an antiviral mechanism of type III CRISPR-Cas-regulated adenosine triphosphate (ATP) depletion in which ATP is converted into inosine triphosphate (ITP) by CRISPR-Cas-associated adenosine deaminase (CAAD) upon activation by either cA<sub>4</sub> or cA<sub>6</sub>, followed by hydrolysis into inosine monophosphate (IMP) by Nudix hydrolase, ultimately resulting in cell growth arrest. The cryo-electron microscopy structures of CAAD in its apo and activated forms, together with biochemical evidence, revealed how cA<sub>4</sub> or cA<sub>6</sub> binds to the CRISPR-associated Rossmann fold (CARF) domain and abrogates CAAD autoinhibition, inducing substantial conformational changes that reshape the structure of CAAD and induce its deaminase activity. Our results reveal the mechanism of a CRISPR-Cas-regulated ATP depletion antiviral strategy.
Medical subject headings
- Adenosine Deaminase
- Adenosine Triphosphate
- CRISPR-Associated Proteins
- CRISPR-Cas Systems
- Verrucomicrobia